|
UNC50 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 4.50070000046487E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.78786999999181E-05 |
| Normal-vs-Stage2 |
1.614640E-04 |
| Normal-vs-Stage3 |
3.66949999996979E-06 |
| Normal-vs-Stage4 |
4.3904000002204E-07 |
| Stage1-vs-Stage2 |
2.905200E-01 |
| Stage1-vs-Stage3 |
2.464800E-01 |
| Stage1-vs-Stage4 |
8.112300E-02 |
| Stage2-vs-Stage3 |
7.395800E-01 |
| Stage2-vs-Stage4 |
7.740600E-01 |
| Stage3-vs-Stage4 |
4.160200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
4.55989999981199E-07 |
| Normal-vs-AfricanAmerican |
3.364300E-02 |
| Normal-vs-Asian |
4.856400E-03 |
| Caucasian-vs-AfricanAmerican |
2.660200E-01 |
| Caucasian-vs-Asian |
2.543200E-01 |
| AfricanAmerican-vs-Asian |
8.212000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
4.41850000032495E-07 |
| Normal-vs-Female |
2.51380000004797E-06 |
| Male-vs-Female |
3.521000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.58506999999863E-05 |
| Normal-vs-Age(41-60Yrs) |
5.91970000000108E-05 |
| Normal-vs-Age(61-80Yrs) |
1.12389999973317E-07 |
| Normal-vs-Age(81-100Yrs) |
5.443900E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.399600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.340650E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.833600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.077580E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.885600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.548800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.641200E-01 |
| Classical-VS-Follicular |
1.435800E-01 |
| Classical-VS-Other |
6.979200E-01 |
| Classical-VS-Normal |
2.71470000001717E-06 |
| Tall-VS-Follicular |
7.608600E-01 |
| Tall-VS-Other |
9.447600E-01 |
| Tall-VS-Normal |
4.417900E-04 |
| Follicular-VS-Other |
8.517600E-01 |
| Follicular-VS-Normal |
2.27449999999907E-05 |
| Other-VS-Normal |
5.238500E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.86053999999825E-05 |
| Normal-vs-N1 |
3.97730000000207E-05 |
| N0-vs-N1 |
5.584000E-01 |
|
|
